Lexicon Pharmaceuticals Inc [NASDAQ: LXRX] closed the trading session at $1.34 on 2025-09-25. The day’s price range saw the stock hit a low of $1.27, while the highest price level was $1.37.
The stocks have a year to date performance of -19.28 percent and weekly performance of 9.84 percent. The stock has been moved at 307.29 percent over the last six months. The stock has performed 17.54 percent around the most recent 30 days and changed 44.19 percent over the most recent 3-months.
If compared to the average trading volume of 3.21M shares, LXRX reached to a volume of 3718308 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Lexicon Pharmaceuticals Inc [LXRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LXRX shares is $2.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LXRX stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Leerink Partners have made an estimate for Lexicon Pharmaceuticals Inc shares, keeping their opinion on the stock as Market Perform, with their previous recommendation back on March 05, 2025. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on June 17, 2024, representing the official price target for Lexicon Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $5, while Leerink Partners analysts kept a Outperform rating on LXRX stock.
The Price to Book ratio for the last quarter was 3.76, with the Price to Cash per share for the same quarter was set at 0.38.
LXRX stock trade performance evaluation
Lexicon Pharmaceuticals Inc [LXRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 9.84. With this latest performance, LXRX shares gained by 17.54% in over the last four-week period, additionally plugging by 307.29% over the last 6 months – not to mention a rise of 81.45% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LXRX stock in for the last two-week period is set at 66.48, with the RSI for the last a single of trading hit 0.0822, and the three-weeks RSI is set at 0.0793 for Lexicon Pharmaceuticals Inc [LXRX]. The present Moving Average for the last 50 days of trading for this stock 1.1420, while it was recorded at 1.2460 for the last single week of trading, and 0.7972 for the last 200 days.
Lexicon Pharmaceuticals Inc [LXRX]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Lexicon Pharmaceuticals Inc [LXRX] shares currently have an operating margin of -187.35% and a Gross Margin at 98.14%. Lexicon Pharmaceuticals Inc’s Net Margin is presently recorded at -206.43%.
Lexicon Pharmaceuticals Inc (LXRX) Capital Structure & Debt Analysis
According to recent financial data for Lexicon Pharmaceuticals Inc. ( LXRX), the Return on Equity (ROE) stands at -65.30%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -40.28%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Lexicon Pharmaceuticals Inc’s Return on Invested Capital (ROIC) is -63.49%, showcasing its effectiveness in deploying capital for earnings.
Lexicon Pharmaceuticals Inc (LXRX) Efficiency & Liquidity Metrics
Based on Lexicon Pharmaceuticals Inc’s (LXRX) latest financial statements, the Debt-to-Equity Ratio is 0.47%, indicating its reliance on debt financing relative to shareholder equity.
Lexicon Pharmaceuticals Inc (LXRX) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Lexicon Pharmaceuticals Inc. (LXRX) effectively leverages its workforce, generating an average of -$1171067.96 per employee. The company’s liquidity position is robust, with a Current Ratio of 4.16% and a Quick Ratio of 4.16%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Lexicon Pharmaceuticals Inc [LXRX] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LXRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Lexicon Pharmaceuticals Inc go to 31.00%.
Lexicon Pharmaceuticals Inc [LXRX]: Institutional Ownership
There are presently around $72.06%, or 72.92%% of LXRX stock, in the hands of institutional investors. The top three institutional holders of LXRX stocks are: ARTAL GROUP S.A. with ownership of 175.1 million shares, which is approximately 56.3318%. FMR LLC, holding 38.69 million shares of the stock with an approximate value of $$64.99 million in LXRX stocks shares; and FMR LLC, currently with $$16.62 million in LXRX stock with ownership which is approximately 3.1818%.
